357 related articles for article (PubMed ID: 22931300)
1. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
[TBL] [Abstract][Full Text] [Related]
2. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development.
Reese M; Sakatis M; Ambroso J; Harrell A; Yang E; Chen L; Taylor M; Baines I; Zhu L; Ayrton A; Clarke S
Chem Biol Interact; 2011 Jun; 192(1-2):60-4. PubMed ID: 20970409
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity.
Feng S; He X
Curr Drug Metab; 2013 Nov; 14(9):921-45. PubMed ID: 24016115
[TBL] [Abstract][Full Text] [Related]
6. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.
Bauman JN; Kelly JM; Tripathy S; Zhao SX; Lam WW; Kalgutkar AS; Obach RS
Chem Res Toxicol; 2009 Feb; 22(2):332-40. PubMed ID: 19161298
[TBL] [Abstract][Full Text] [Related]
7. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
Yan Z; Caldwell GW
Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
[TBL] [Abstract][Full Text] [Related]
8. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury.
Yano A; Oda S; Fukami T; Nakajima M; Yokoi T
Toxicol Lett; 2014 Jul; 228(1):13-24. PubMed ID: 24747151
[TBL] [Abstract][Full Text] [Related]
9. The use of hepatocytes to investigate drug toxicity.
Gómez-Lechón MJ; Castell JV; Donato MT
Methods Mol Biol; 2010; 640():389-415. PubMed ID: 20645064
[TBL] [Abstract][Full Text] [Related]
10. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
Tang W; Lu AY
Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
[TBL] [Abstract][Full Text] [Related]
11. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
12. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
13. Metabolic activation in drug-induced liver injury.
Leung L; Kalgutkar AS; Obach RS
Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
Gómez-Lechón MJ; Tolosa L; Donato MT
J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
[TBL] [Abstract][Full Text] [Related]
15. Assessment of reactive metabolites in drug-induced liver injury.
Lee KS; Oh SJ; Kim HM; Lee KH; Kim SK
Arch Pharm Res; 2011 Nov; 34(11):1879-86. PubMed ID: 22139687
[TBL] [Abstract][Full Text] [Related]
16. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
Pessayre D; Benhamou JP
C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767
[TBL] [Abstract][Full Text] [Related]
17. A high content screening assay to predict human drug-induced liver injury during drug discovery.
Persson M; Løye AF; Mow T; Hornberg JJ
J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
[TBL] [Abstract][Full Text] [Related]
18. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
Chen M; Borlak J; Tong W
Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved.
Martínez-Sena T; Moro E; Moreno-Torres M; Quintás G; Hengstler J; Castell JV
Arch Toxicol; 2023 Jun; 97(6):1723-1738. PubMed ID: 37022445
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-Mediated Bioactivation: Implication for the Liver Injury Induced by Fraxinellone, A Bioactive Constituent from Dictamni Cortex.
Zhou H; Liu Q; Zhang J; Yao J; Wang C; Zhang Y; Li Y; Zhang X; Zhang L
Chem Res Toxicol; 2020 Jul; 33(7):1960-1968. PubMed ID: 32484342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
